Interpace Biosciences, Inc. (IDXG) Return on equity 2017–2025
Interpace Biosciences, Inc. (IDXG) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
109.9%FY2025 · since FY2017: 54.8% → 109.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 109.9% | — |
| FY2018 | -82.2% | -137.1 pp |
| FY2017 | 54.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice